Company profile

Sol-Gel Technologies Ltd.

Pipeline4 assets

patidegibSGT-610 / Hedgehog signaling pathway (SMO) / Small molecule / Dermatology
Gorlin syndrome (prevention of new BCC lesions)High-frequency basal cell carcinoma (BCC)
erlotinibSGT-210 / EGFR / Small molecule / Dermatology
Undisclosed indications
tretinoin and benzoyl peroxide cream, 0.1%/3%TWYNEO / Retinoid receptors / Bacterial proteins / Small molecule / Dermatology
Acne vulgaris
benzoyl peroxide cream, 5%EPSOLAY / Bacterial proteins / Small molecule / Dermatology
Inflammatory lesions of rosacea

Latest news3 items

Sep 17, 2026

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

Enrollment • Phase 3Top-line results Mon, Nov 30, 2026

Aug 20, 2026

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 Sol-Gel has initiated a proof-of-concept study in High-frequency BCC (HF-BCC) Sol-Gel initiated a study evaluating topical

May 28, 2026

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist